title: The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
abstract: OBJECTIVE
  To investigate the characteristics of Hep-2 cell with multidrug resistance (MDR) induced by Taxol.
  
  
  METHODS
  Hep-2 cells were exposed in stepwise escalating concentration of Taxol to develop the resistant cell line-Hep-2T. Cell cycle distribution, apoptosis, and rhodamine accumulation were studied through flow cytometry. The MDR1 and MRP1 genes were detected through real-time quantitative RT-PCR, and the corresponding proteins were detected through Western blotting.
  
  
  RESULTS
  The drug resistance of Hep-2T cells to Taxol, doxorubicin, gemcitabine, 5-FU, and cisplatin all increased. The percentage of G0/G1 phase and the antiapoptosis ability increased significantly compared with Hep-2 cells. Both MDR1 and MRP1 also increased at gene and protein level, though MDR1 was more prominent.
  
  
  CONCLUSIONS
  More emphasis should be laid on MDR1/Pgp, the non-Pgp substrate chemotherapeutic agents, and the changes of cell cycle distribution to prevent MDR induced by Taxol.
  
  
  CONCLUSIONS
  These findings may provide theoretical support for the reverse of MDR.
authors: Department of Otolaryngology, Shanghai Jiao Tong University affiliated First People's Hospital, China.
authors: Li
authors: L
authors: Li
authors: Alice C
authors: AC
authors: Jiang
authors: Pin
authors: P
authors: Dong
authors: Yi
authors: Y
authors: Wan
authors: Zi Wei
authors: ZW
authors: Yu
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000032:analysis; D017239:Paclitaxel / Q000627:therapeutic use*; D020112:Rhodamine 123; D000093542:Gemcitabine
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D002945:Cisplatin; D003841:Deoxycytidine; D004317:Doxorubicin; D005456:Fluorescent Dyes; D005472:Fluorouracil; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D017239:Paclitaxel; D020112:Rhodamine 123; D000093542:Gemcitabine; C513055:ABCB1 protein, human; C421109:multidrug resistance-associated protein 1